LIDO (Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving)

Study ID
STU 032013-049

Cancer Related

Healthy Volunteers

Study Sites

  • UT Southwestern-Other
  • Dallas Veteran's Affairs Medical Center
  • Zale Lipshy University Hospital
  • CTRC Inpatient

Sabrina Blackledge

Principal Investigator
Bryon Adinoff, M.D.


in this proof-of-concept approach for the treatment of cocaine addition (modeled on a paradigm developed by our group to assess pharmacologic disruptors of PTSD-related trauma memories), the effect of lidocaine infusion following cue-induced craving will be assessed in treatment-seeking, cocaine-addicted participants. immediately following the induction of cue-induced craving, lidocaine or saline will be administered in a double-blind, randomized design. a third arm will also assess lidocaine in the absence of cue-induced craving. one week following the infusion, cue-induced craving will be assessed. Cocaine use and craving (non cue-induced) will be monitored for four weeks.

Participant Eligibility

All participants must be 25-60 years old, of either sex, and of any race. The relatively small sample size necessitates that variability be limited. As treatment-seeking, cocaine-addicted subjects in our previous studies had mean(+ or -)SD ages of 39(+ or -)4 (25 men) and 36(+ or -)7 (10 women) (4), 37(+ or -)7 (n=23), and 44(+ or -)7 (n=64) (75% of the subjects were between 30 and 50 y/o), the age range will be limited to 25-60 y/o. Patients will be inpatient or outpatient and treatment seeking. Patients must meet DSM-IV criteria for cocaine dependence (by Structured Clinical Interview DSM-IV Lifetime) and must identify cocaine as their primary present and lifetime drug of abuse. Participants must live close enough to the sites and have reliable transportation such that they can attend all assessments, study sessions, and follow-up and treatment sessions.